Codexis, Inc. revenue
Codexis, Inc.'s revenue was $70.4m in fiscal 2025, up 18.6% on the year before. Since fiscal 2009 ($82.9m) it has grown at a compound -1.0% a year. Over the last twelve months it was $77.7m.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 83 | 107 | 124 | 88 | 32 | 35 | 42 | 49 | 50 | 61 | 68 | 69 | 105 | 139 | 70 | 59 | 70 | 78 |
| Growth on the year before | — | +29.2% | +15.6% | −28.7% | −63.8% | +10.6% | +18.4% | +16.8% | +2.4% | +21.1% | +13.0% | +0.9% | +51.7% | +32.3% | −49.4% | −15.4% | +18.6% | — |
| Gross profit | — | — | — | — | — | — | — | 39 | 36 | 48 | 53 | 55 | 83 | 101 | 57 | 43 | 61 | 68 |
| Gross margin | — | — | — | — | — | — | — | 80.0% | 71.4% | 79.2% | 77.2% | 80.1% | 78.8% | 72.6% | 81.7% | 72.6% | 86.7% | 87.0% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Research and Development Revenue | $44.4M | 63.0% | ▲ 96.6% |
| Products | $26M | 37.0% | ▼ 29.2% |
| Region | Revenue | YoY |
|---|---|---|
| Americas | $43.5M | ▲ 104.6% |
| United States | $43.5M | ▲ 104.2% |
| Asia Pacific | $17.6M | ▼ 36.6% |
| China | $9.3M | ▼ 5.1% |
| EMEA | $9.3M | ▼ 10.3% |
| India | $5.7M | ▼ 21.9% |
| Switzerland | $4.2M | ▲ 23.5% |
| Ireland | $700,000 | ▼ 61.1% |
| Singapore | $400,000 | ▼ 93.5% |
These categories overlap or exclude eliminations, so shares aren't shown.
From Codexis, Inc.'s 10-K filed March 11, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Codexis, Inc. | $77.7m | 35.9% | -7.8% |
| Burning Rock Biotech Ltd | $75.1m | 4.7% | — |
| Exagen Inc. | $71.1m | 20.8% | 10.3% |
| Personalis, Inc. | $69.7m | -13.3% | 1.2% |
| Harvard Bioscience Inc | $87.8m | -1.1% | -8.4% |
| 908 Devices Inc. | $60.8m | 13.4% | 7.5% |
Compare with peers
- Burning Rock Biotech Ltd revenue
- Exagen Inc. revenue
- Personalis, Inc. revenue
- Harvard Bioscience Inc revenue
- 908 Devices Inc. revenue
Head to head: BNR vs CDXSCDXS vs XGNCDXS vs PSNLCDXS vs HBIO
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies